Next 10 |
Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo...
Gainers : Mustang Bio (NASDAQ: MBIO ) +117% . Checkpoint Therapeutics (NASDAQ: CKPT ) +19% . Amyris (NASDAQ: AMRS ) +18% . Uxin (NASDAQ: UXIN ) +17% . Viomi Technology (NASDAQ: VIOT ) +16% . Fortress Biotech (NASDAQ: FBIO ) +15% . Broadwind Energy (NASDAQ: BWEN ) +13% . Libbey (NYSE...
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement da...
The board of OncoMed Pharmaceuticals (NASDAQ: OMED ) has declared a one-time special dividend to stockholders in the form of a contractual right to receive cash payments related to Celgene's (NASDAQ: CELG ) option on etigilimab. More news on: OncoMed Pharmaceuticals, Inc., Celgene Corpor...
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declar...
OncoMed (NASDAQ: OMED ): Q4 GAAP EPS of -$0.12. More news on: OncoMed Pharmaceuticals, Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
REDWOOD CITY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced fourth quarter and full year 2018 financial results. Rec...
With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. ( CGEN ) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months. Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen ...
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Offic...
News, Short Squeeze, Breakout and More Instantly...
OncoMed Pharmaceuticals Inc. Company Name:
OMED Stock Symbol:
NASDAQ Market:
OncoMed Pharmaceuticals Inc. Website:
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo...
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement da...
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declar...